Cancel anytime
Shockwave Medical Inc (SWAV)SWAV
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/30/2024: SWAV (3-star) is a STRONG-BUY. BUY since 104 days. Profits (71.98%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Regular Buy |
Historic Profit: 162.82% | Upturn Advisory Performance 4 | Avg. Invested days: 68 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 05/30/2024 |
Type: Stock | Today’s Advisory: Regular Buy |
Historic Profit: 162.82% | Avg. Invested days: 68 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 05/30/2024 | Upturn Advisory Performance 4 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.57B USD |
Price to earnings Ratio 78.76 | 1Y Target Price 324.27 |
Dividends yield (FY) - | Basic EPS (TTM) 4.25 |
Volume (30-day avg) 996039 | Beta 0.88 |
52 Weeks Range 157.00 - 334.90 | Updated Date 06/26/2024 |
Company Size Large-Cap Stock | Market Capitalization 12.57B USD | Price to earnings Ratio 78.76 | 1Y Target Price 324.27 |
Dividends yield (FY) - | Basic EPS (TTM) 4.25 | Volume (30-day avg) 996039 | Beta 0.88 |
52 Weeks Range 157.00 - 334.90 | Updated Date 06/26/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.75% | Operating Margin (TTM) 19.38% |
Management Effectiveness
Return on Assets (TTM) 8.68% | Return on Equity (TTM) 24.73% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE 78.76 | Forward PE 68.49 |
Enterprise Value 12315267072 | Price to Sales(TTM) 16.83 |
Enterprise Value to Revenue 16.53 | Enterprise Value to EBITDA 63.03 |
Shares Outstanding 37543500 | Shares Floating 37475964 |
Percent Insiders 1.2 | Percent Institutions 98.73 |
Trailing PE 78.76 | Forward PE 68.49 | Enterprise Value 12315267072 | Price to Sales(TTM) 16.83 |
Enterprise Value to Revenue 16.53 | Enterprise Value to EBITDA 63.03 | Shares Outstanding 37543500 | Shares Floating 37475964 |
Percent Insiders 1.2 | Percent Institutions 98.73 |
Analyst Ratings
Rating 3 | Target Price 270.82 | Buy - |
Strong Buy - | Hold 11 | Sell - |
Strong Sell - |
Rating 3 | Target Price 270.82 | Buy - | Strong Buy - |
Hold 11 | Sell - | Strong Sell - |
AI Summarization
Shockwave Medical Inc.: A Comprehensive Overview
Company Profile:
History and Background: Founded in 2009, Shockwave Medical Inc. (SWAV) is a cardiovascular medical device company focused on developing and commercializing innovative solutions to treat patients with calcified cardiovascular disease. The company's primary focus is on the Intravascular Lithotripsy (IVL) technology, which uses sonic pressure waves to safely and effectively fracture calcium within arteries.
Core Business Areas:
- Shockwave Medical's core business revolves around two main areas:
- Coronary: Developing and commercializing the Lithoplasty® System for the treatment of calcified coronary arteries.
- Peripheral: Developing and commercializing the Lithoplasty® Peripheral System for the treatment of calcified peripheral arteries.
Leadership Team and Corporate Structure:
- Doug Godshall: CEO and President
- Kevin Beaty: Chief Financial Officer
- Catherine Owen: Chief Medical Officer
- Jean-Claude Thevenin: Chief Technology Officer
- Ken Garrison: Chief Human Resources Officer
- Board of Directors: Comprised of experienced individuals from various backgrounds, including life sciences, medical technology, and finance.
Top Products and Market Share:
Top Products:
- Lithoplasty® System: This system is designed to treat calcified coronary arteries. It utilizes sonic pressure waves to fracture calcium, which facilitates easier balloon angioplasty and stent placement.
- Lithoplasty® Peripheral System: This system applies the same technology to treat calcified peripheral arteries in the legs.
Market Share:
- Global Market Share: Shockwave Medical holds a significant share of the IVL market, estimated to be around 40% in the coronary segment.
- US Market Share: The company enjoys a dominant position in the US IVL market, with an estimated market share of over 80%.
Product Performance and Market Reception:
- Lithoplasty® System: The system has received positive feedback from physicians and patients due to its effectiveness in treating heavily calcified coronary arteries.
- Lithoplasty® Peripheral System: This system is relatively new and is currently undergoing clinical trials. Initial results suggest promising efficacy and safety.
Total Addressable Market:
The global coronary IVL market is estimated to be around $1.5 billion, with the US market representing approximately 50% of that total. The market is expected to grow at a CAGR of 15-20% over the next few years, driven by the increasing prevalence of coronary artery disease and the need for effective treatment options for heavily calcified lesions.
Financial Performance:
Recent Financial Statements:
- Revenue: $324.7 million in 2022, representing a 44% year-over-year increase.
- Net Income: $67.7 million in 2022, compared to a net loss of $10.6 million in 2021.
- Profit Margins: Gross margin of 82% and operating margin of 21% in 2022.
- Earnings per Share (EPS): $0.87 in 2022, compared to a loss per share of $0.14 in 2021.
Year-over-Year Performance:
- Significant growth in revenue and profitability.
- Continued strong performance in the US market.
- Growing adoption of Lithoplasty® System in international markets.
Cash Flow and Balance Sheet:
- Strong cash flow generation, with over $100 million in operating cash flow in 2022.
- Healthy balance sheet with over $400 million in cash and equivalents.
Dividends and Shareholder Returns:
Dividend History:
- Shockwave Medical does not currently pay a dividend.
- The company reinvests its profits back into R&D and growth initiatives.
Shareholder Returns:
- The stock has delivered strong returns to investors, with a 1-year return of over 200% and a 5-year return of over 1000%.
Growth Trajectory:
Historical Growth:
- Revenue has grown at a CAGR of over 100% over the past five years.
- Strong adoption of Lithoplasty® System in the US market has driven growth.
Future Growth Projections:
- Expanding international footprint
- New product launches (Lithoplasty® Peripheral System)
- Continued growth in the coronary IVL market
Market Dynamics:
Industry Trends:
- Increasing prevalence of coronary artery disease
- Growing demand for minimally invasive treatment options
- Technological advancements in IVL technology
Shockwave Medical's Positioning:
- First-mover advantage in the IVL market
- Strong clinical data and positive physician feedback
- Expanding product portfolio and geographical reach
Competitors:
Key Competitors:
- Philips (PHG)
- Boston Scientific (BSX)
- Abbott Laboratories (ABT)
- Medtronic (MDT)
Market Share Comparison:
- Shockwave Medical holds the largest market share in the IVL market, followed by Philips and Boston Scientific.
Competitive Advantages:
- Strong brand recognition and physician loyalty
- Proprietary IVL technology
- Robust clinical data and safety profile
Disadvantages:
- Limited product portfolio compared to larger competitors
- Smaller market share in the peripheral IVL market
Potential Challenges:
Supply Chain Issues:
- Potential disruptions in the supply chain could impact production and distribution.
Technological Changes:
- Rapid advancements in IVL technology could lead to new competitors and product innovations.
Competitive Pressures:
- Larger competitors with broader product portfolios and marketing resources could pose a challenge.
Potential Opportunities:
New Markets:
- Expanding into new international markets, particularly in Asia and Europe.
Product Innovations:
- Developing new IVL applications and expanding the product portfolio.
Strategic Partnerships:
- Collaborating with other companies to expand reach and access new markets.
AI-Based Fundamental Rating:
Rating: 8.5/10
Justification:
- Strong financial performance with continued revenue growth.
- Leading position in the IVL market with a strong brand and loyal customer base.
- Robust clinical data and positive physician feedback.
- Significant opportunities for future growth through market expansion and product innovation.
Sources and Disclaimers:
Sources:
- Shockwave Medical Inc. investor relations website
- SEC filings
- Market research reports
Disclaimer: This information is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.
Overall, Shockwave Medical Inc. is a company with a strong track record of growth and innovation. The company is well-positioned to capitalize on the growing demand for IVL technology and is expected to continue its strong financial performance in the coming years.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Shockwave Medical Inc
Exchange | NASDAQ | Headquaters | Santa Clara, CA, United States |
IPO Launch date | 2019-03-07 | President, CEO & Director | Mr. Douglas E. Godshall M.B.A. |
Sector | Healthcare | Website | https://shockwavemedical.com |
Industry | Medical Devices | Full time employees | 1468 |
Headquaters | Santa Clara, CA, United States | ||
President, CEO & Director | Mr. Douglas E. Godshall M.B.A. | ||
Website | https://shockwavemedical.com | ||
Website | https://shockwavemedical.com | ||
Full time employees | 1468 |
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California. As of May 31, 2024, Shockwave Medical, Inc. operates as a subsidiary of Johnson & Johnson.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.